SCM
Soleus Capital Management Portfolio holdings
AUM
$2.36B
1-Year Est. Return
93.5%
This Fund
S&P 500
1 Year Est. Return
+93.5%
AUM
$1.87B
AUM Growth
+$423M
(+29%)
Holding
113
Top Buys
| 1 | +$62.7M | |
| 2 | +$59M | |
| 3 | +$52.7M | |
| 4 |
Twist Bioscience
TWST
|
+$45.8M |
| 5 |
NovoCure
NVCR
|
+$36.6M |
Top Sells
| 1 | +$73.4M | |
| 2 | +$59.2M | |
| 3 | +$37.3M | |
| 4 |
Grifois
GRFS
|
+$32.5M |
| 5 |
UroGen Pharma
URGN
|
+$27M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Orthofix Medical
OFIX
$507M
| – | – |
-261,147
|
|
||
102
Revolution Medicines
RVMD
$19.5B
| – | – |
-10,000
|
|
||
103
The Beauty Health Co
SKIN
$145M
| – | – |
-1,000,000
|
|
||
104
Soleno Therapeutics
SLNO
$2.13B
| – | – |
-10,000
|
|
||
|
SRDX
105
DELISTED
Surmodics
SRDX
| – | – |
-789,060
|
|
||
106
Scholar Rock
SRRK
$4.62B
| – | – |
-125,000
|
|
||
107
UnitedHealth
UNH
$260B
| – | – |
-86,250
|
|
||
108
GeneDx Holdings
WGS
$2.58B
| – | – |
-40,000
|
|
||
109
State Street SPDR S&P Biotech ETF
XBI
$8.12B
| – | – |
0
|
|
||
110
Xenon Pharmaceuticals
XENE
$3.24B
| – | – |
-78,800
|
|
||
|
YMAB
111
DELISTED
Y-mAbs Therapeutics
YMAB
| – | – |
-349,982
|
|
||
|
THTX
112
DELISTED
Theratechnologies
THTX
| – | – |
-4,801,376
|
|
||
113
Tandem Diabetes Care
TNDM
$1.44B
| – | – |
-200,000
|
|